X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62) 62
index medicus (62) 62
female (55) 55
oncology (45) 45
middle aged (41) 41
cancer (38) 38
adult (37) 37
aged (35) 35
male (32) 32
medicine & public health (30) 30
analysis (25) 25
chemotherapy (20) 20
cancer research (18) 18
care and treatment (16) 16
retrospective studies (16) 16
aged, 80 and over (15) 15
tumors (14) 14
obstetrics & gynecology (13) 13
surgical oncology (13) 13
carcinoma (12) 12
japan (12) 12
patients (12) 12
colorectal cancer (11) 11
prognosis (11) 11
adenocarcinoma (10) 10
disease-free survival (10) 10
metastasis (10) 10
original (10) 10
pharmacology/toxicology (10) 10
expression (9) 9
immunohistochemistry (9) 9
mutation (9) 9
pharmacology & pharmacy (9) 9
research (9) 9
survival (9) 9
therapy (9) 9
animals (8) 8
antineoplastic agents - adverse effects (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cervical cancer (8) 8
colorectal neoplasms - drug therapy (8) 8
gastroenterology & hepatology (8) 8
neoplasm staging (8) 8
original article (8) 8
risk (8) 8
studies (8) 8
surgery (8) 8
treatment outcome (8) 8
trial (8) 8
young adult (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
camptothecin - analogs & derivatives (7) 7
diagnosis (7) 7
endometrial cancer (7) 7
gastroenterology (7) 7
medical colleges (7) 7
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
camptothecin - administration & dosage (6) 6
cancer patients (6) 6
cisplatin (6) 6
disease progression (6) 6
fluorouracil (6) 6
gynecologic-oncology-group (6) 6
hematology, oncology and palliative medicine (6) 6
internal medicine (6) 6
irinotecan (6) 6
medical prognosis (6) 6
medicine (6) 6
mice (6) 6
obstetrics and gynecology (6) 6
ovarian cancer (6) 6
research article (6) 6
time factors (6) 6
vaccination (6) 6
vaccines (6) 6
women (6) 6
antineoplastic agents - administration & dosage (5) 5
cell line, tumor (5) 5
chemotherapy, adjuvant (5) 5
colorectal neoplasms - pathology (5) 5
development and progression (5) 5
double-blind (5) 5
gastric cancer (5) 5
genes (5) 5
immunology (5) 5
japan - epidemiology (5) 5
kaplan-meier estimate (5) 5
kinases (5) 5
lung cancer (5) 5
medical screening (5) 5
monoclonal antibodies (5) 5
multicenter (5) 5
multidisciplinary sciences (5) 5
oncology, experimental (5) 5
phase-iii trial (5) 5
progression-free survival (5) 5
safety (5) 5
uterine cervical neoplasms - prevention & control (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 499 - 508
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis | Life Sciences | Human health and pathology
Journal Article
Gastric Cancer, ISSN 1436-3291, 5/2017, Volume 20, Issue 3, pp. 407 - 415
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2019, Volume 19, Issue 1, pp. 1 - 7
Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in many malignancies.... 
Development and progression | Care and treatment | Colitis | Biomarker | Case report | Autoimmune colitis | C-reactive protein | Immune-related adverse event | Nivolumab
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1013 - 1021
Journal Article
Modern Rheumatology, ISSN 1439-7595, 2/2012, Volume 22, Issue 1, pp. 1 - 14
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2013, Volume 8, Issue 6, p. e67466
Background: Epithelial cell adhesion molecule (EpCAM)-based enumeration of circulating tumor cells (CTC) has prognostic value in patients with solid tumors,... 
BREAST-CANCER | SURVIVAL | IMPACT | MULTIDISCIPLINARY SCIENCES | PERIPHERAL-BLOOD | PROGRESSION | CLINICAL-SIGNIFICANCE | Prognosis | Prospective Studies | Neoplastic Cells, Circulating - pathology | Cell Count | Humans | Lung Neoplasms - metabolism | Middle Aged | Neoplastic Cells, Circulating - metabolism | Lung Neoplasms - pathology | Male | Tissue Array Analysis - methods | Small Cell Lung Carcinoma - blood | Epithelial Cell Adhesion Molecule | Small Cell Lung Carcinoma - metabolism | Aged, 80 and over | Antigens, Neoplasm - metabolism | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Cell Adhesion Molecules - metabolism | Small Cell Lung Carcinoma - pathology | Cell Line, Tumor | Carcinoma, Non-Small-Cell Lung - blood | Aged | Lung Neoplasms - blood | Medical research | Care and treatment | Medicine, Experimental | Metastasis | Comparative analysis | Lung cancer, Non-small cell | Prostate cancer | Biotechnology | Epithelial cells | Lung cancer | Oncology | Statistical methods | Metastases | Cell adhesion molecules | Engineering | Colon cancer | Cell adhesion | Peripheral blood | Clusters | Life sciences | Colon | Enumeration | Statistical analysis | Research & development--R&D | Tumor cells | Non-small cell lung carcinoma | Breast cancer | Statistics | Patients | Chemotherapy | Sampling methods | Solid tumors | Median (statistics) | Prostate | Tumors | Cancer | Research & development | R&D
Journal Article
by Nishida, Toshirou and Sakai, Yoshiharu and Takagi, Masakazu and Ozaka, Masato and Kitagawa, Yuko and Kurokawa, Yukinori and Masuzawa, Toru and Naito, Yoichi and Kagimura, Tatsuo and Hirota, Seiichi and Saito, Takuro and Komatsu, Yoshito and Kondo, Masato and Hayashi, Tsutomu and Gotoda, Naoto and Takiguchi, Nobuhiro and Maki, Atsuhiko and Baba, Hideo and Orita, Hajime and Yabusaki, Hiroshi and Chiguchi, Gaku and Manaka, Dai and Nabeshima, Kazuhito and Akabane, Hiromitsu and Ono, Koichi and Wada, Norihito and Kaji, Masahide and Yoshida, Kazuhiro and Takahashi, Ikuo and Fujitani, Kazumasa and Matsumoto, Sohei and Tamamori, Yutaka and Saito, Hiroaki and Ueda, Shugo and Yamamura, Masahiro and Fujii, Hirofumi and Yoshino, Shigefumi and Suzuki, Akihiro and Otsuji, Eigo and Kawachi, Shigeyuki and Takahashi, Tsuyoshi and Muguruma, Kazuya and Ishikawa, Suguru and Mitsutsuji, Masaaki and Takamori, Hiroshi and Kaiho, Takashi and Sako, Akihiro and Ito, Seiji and Mori, Masahiro and Tokuhara, Makoto and Kawaguchi, Yoshihiko and Hirabayashi, Naoki and Yoshida, Motohira and Takahashi, Masazumi and Takase, Shiro and Yamashita, Keishi and Iwasaki, Yoshiaki and Ozeki, Yutaka and Nishida, Yasunori and Koeda, Keisuke and Tsujinaka, Toshimasa and Kanie, Hiroshi and Hato, Shinji and Morimoto, Junya and Honda, Hiroshi and Tashiro, Hirotaka and Kakeji, Yoshihiro and Hata, Hiroaki and Sugiyama, Toshiro and Nobuoka, Takayuki and Fukushima, Ryoji and Sugiyama, Katsuro and Hasegawa, Junichi and Yoshimura, Tsunehiro and Takashima, Atsuo and Kunisaki, Chikara and Shinozaki, Hiroharu and Senmaru, Naoto and Imamura, Hiroshi and Otsu, Satoshi and Kobayashi, Daisuke and Noguchi, Akinori and Takagane, Akinori and Mitsunaga, Atsushi and Tamura, Shigeyuki and Matsuyama, Jin and Oka, Yoshio and Kajiyama, Kiyoshi and Yamada, Takuji and Hoshino, Sumito and Ohdan, Hideki and Kakishita, Tomokazu and Yanaga, Katsuhiko and Rino, Yasushi and Takahashi, Takayuki and Matsubara, Hisahiro and Ishizaki, Masahiro and Kim, Songtae and Inaki, Noriyuki and Hirahara, Noriyuki and ... and members of the STAR ReGISTry Study Group and The members of the STAR ReGISTry Study Group
Gastric Cancer, ISSN 1436-3291, 2019, pp. 1 - 8
A multidisciplinary approach based on guidelines and pathological diagnosis by specialized pathologists are important for improving the prognosis and QoL of... 
Multidisciplinary board | Pathological diagnosis | Adjuvant therapy | Gastrointestinal stromal tumor | Guidelines | Pathology | Imatinib | Genotyping | Risk groups | Mitosis | Diagnosis | Multivariate analysis | Stomach cancer | Tumors
Journal Article